SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

Company Overview

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Key Stats

• Today's Range: $46.99 to $46.99
• 50-Day Range: $46.46 to $46.99
• 52-Week Range: $28.21 to $62.00
• Volume: N/A
• Average Volume: 2.66 million shs
• Market Capitalization: $3.54 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $52.57
• Consensus Rating: Hold

SpringWorks Therapeutics Stock Analysis - MarketRank™

SpringWorks Therapeutics scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

SpringWorks Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

SpringWorks Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($2.05) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SpringWorks Therapeutics is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SpringWorks Therapeutics is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SpringWorks Therapeutics has a P/B Ratio of 7.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SWTX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SpringWorks Therapeutics does not currently pay a dividend.

Dividend Growth

SpringWorks Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for SWTX.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for SpringWorks Therapeutics this week, compared to 7 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SpringWorks Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.83% of the stock of SpringWorks Therapeutics is held by insiders.

SWTX Stock Analysis - Frequently Asked Questions

How have SWTX shares performed this year?

SpringWorks Therapeutics' stock was trading at $36.13 at the beginning of 2025. Since then, SWTX shares have increased by 30.1% and is now trading at $46.99.

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics (NASDAQ:SWTX) released its earnings results on Friday, May, 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by $0.30. The business had revenue of $49.09 million for the quarter, compared to the consensus estimate of $64.19 million. SpringWorks Therapeutics had a negative trailing twelve-month return on equity of 51.10% and a negative net margin of 115.60%.

Does SpringWorks Therapeutics have any subsidiaries?

SpringWorks Therapeutics subsidiaries include SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..

When did SpringWorks Therapeutics IPO?

SpringWorks Therapeutics (SWTX) raised $126 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are SpringWorks Therapeutics' major shareholders?

Top institutional shareholders of SpringWorks Therapeutics include Syquant Capital Sas (0.33%), Credit Industriel ET Commercial (0.32%), Palisades Investment Partners LLC (0.18%) and Wolverine Asset Management LLC (0.13%). Insiders that own company stock include Orbimed Advisors Llc, Saqib Islam, Badreddin Edris, Daniel Lynch, Bhavesh Ashar, Daniel Pichl and Julie Hambleton.
View institutional ownership trends.

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SpringWorks Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 8/05/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SWTX
• CIK: 1773427
• Web: www.springworkstx.com
• Phone: 203-883-9490
• Fax: N/A
• Employees: 230
• Year Founded: 2017

Price Target and Rating

• Average Price Target for SpringWorks Therapeutics: $52.57
• High Price Target: $68.00
• Low Price Target: $47.00
• Potential Upside/Downside: +11.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$258.13 million
• Net Margins: -115.60%
• Pretax Margin: -115.60%
• Return on Equity: -51.10%
• Return on Assets: -43.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.33
• Quick Ratio: 4.18

Sales & Book Value

• Annual Sales: $191.59 million
• Price / Sales: 18.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.47 per share
• Price / Book: 7.26

Miscellaneous

• Outstanding Shares: 75,350,000
• Free Float: 69,449,000
• Market Cap: $3.54 billion
• Optionable: Optionable
• Beta: 0.68